Evolving Role of B7-H3–Directed ADCs in the Extensive-Stage Small-Cell Lung Cancer Treatment Landscape

In this podcast episode, Charles Rudin, MD, PhD, and Mark A. Socinski, MD, discuss current gaps and clinical needs for patients with relapsed ES-SCLC, and the evolving role of B7-H3–directed antibody–drug conjugates in the management of patients with ES-SCLC, including: Clinical needs for relapsed ES-SCLC Scientific rationale for targeting B7-H3 and other tumor-associated antigens in SCLC ADCs, T-cell engagers, chemotherapy-based approaches, maintenance strategies, and ongoing clinical trials for ES-SCLC Recent efficacy and safety data for B7-H3–directed ADCs in ES-SCLC, including I-DXd Personalization of care of patients with SCLC, including patient-specific factors influencing treatment Case discussion of a patient with ES-SCLC requiring optimal next best treatment Importance of enrolling patients in ongoing trials of investigational agents for patients with ES-SCLC Presenters: Charles Rudin, MD, PhD Cancer Center Director Memorial Sloan Kettering Cancer Center New York, New York Mark A. Socinski, MD Executive Medical Director AdventHealth Cancer Institute Orlando, Florida Link to full program: https://bit.ly/3UBEeYz Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.